Medivir focus on cancers of high unmet medical need, where existing therapies are not very successful and there is a great opportunity to provide real benefit to patients with few treatment options.
Our pipline include a biologically targeted treatment in combination with an immune-oncology agent (birinapant combination with Keytruda®) to improve outcomes for patients with certain types of solid tumors. We also develop organ targeted treatments to improve efficacy and tolerability for specific cancer types (remetinostat and MIV-818).
have poor treatment options and/or low overall survival rates. In some cases even the best available treatments leave patient needs unmet.